HKSH Medical Group Signed Memorandum of Understanding with Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen To Advance Precision Proton Therapy, Furthering the Healthy China Initiative

(24 December 2025, Hong Kong) In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group (“HKSH”) and Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen (“Shenzhen Cancer Hospital”) signed a memorandum of understanding (“MOU”) on 11 December 2025. The MOU was signed by Dr. Walton LI, Chief Executive Officer of HKSH Medical Group and Medical Superintendent of Hong Kong Sanatorium & Hospital, and Professor WANG Luhua, Director of Shenzhen Cancer Hospital. The signing was witnessed by Mr. Wyman LI, Chief Operating Officer of HKSH Medical Group and Board Member of Hong Kong Sanatorium & Hospital, and Professor HE Jie, Director of the National Cancer Center and Director of the Cancer Hospital Chinese Academy of Medical Sciences. This collaboration aims to enhance collaborative efforts in clinical applications of proton therapy, specialist training, and cancer management research, reinforcing HKSH’s collaboration with the National Cancer Center to address the heightened demand for proton therapy nationwide and to advance collective anti-cancer initiatives.

Please click here for more details.